Yang K - Search Results

1

Overcoming ABCG2-mediated multidrug resistance by a mineralized hyaluronan-drug nanocomplex.

Chen W , Wang F , Zhang X , Hu J , Wang X , Yang K , Huang L , Xu M , Li Q , Fu L . Chen W , et al. Among authors: yang k. J Mater Chem B. 2016 Nov 7;4(41):6652-6661. doi: 10.1039/c6tb01545j. Epub 2016 Oct 7. J Mater Chem B. 2016. PMID: 32263520

2

Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.

Wang XK, To KK, Huang LY, Xu JH, Yang K, Wang F, Huang ZC, Ye S, Fu LW. Wang XK, et al. Among authors: yang k. Oncotarget. 2014 Dec 15;5(23):11971-85. doi: 10.18632/oncotarget.2647. Oncotarget. 2014. PMID: 25436978 Free PMC article.

3

Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.

Yang K, Fu LW. Yang K, et al. Crit Rev Oncol Hematol. 2015 Mar;93(3):277-92. doi: 10.1016/j.critrevonc.2014.11.001. Epub 2014 Nov 13. Crit Rev Oncol Hematol. 2015. PMID: 25500000 Review.

4

Cetuximab enhanced the efficacy of chemotherapeutic agent in ABCB1/P-glycoprotein-overexpressing cancer cells.

Wang F, Chen Y, Huang L, Liu T, Huang Y, Zhao J, Wang X, Yang K, Ma S, Huang L, To KK, Gu Y, Fu L. Wang F, et al. Among authors: yang k. Oncotarget. 2015 Dec 1;6(38):40850-65. doi: 10.18632/oncotarget.5813. Oncotarget. 2015. PMID: 26506420 Free PMC article.

5

Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.

Hu J, Zhang X, Wang F, Wang X, Yang K, Xu M, To KK, Li Q, Fu L. Hu J, et al. Among authors: yang k. Oncotarget. 2015 Dec 29;6(42):44643-59. doi: 10.18632/oncotarget.5989. Oncotarget. 2015. PMID: 26556876 Free PMC article.

6

14-3-3σ Contributes to Radioresistance By Regulating DNA Repair and Cell Cycle via PARP1 and CHK2.

Chen Y, Li Z, Dong Z, Beebe J, Yang K, Fu L, Zhang JT. Chen Y, et al. Among authors: yang k. Mol Cancer Res. 2017 Apr;15(4):418-428. doi: 10.1158/1541-7786.MCR-16-0366. Epub 2017 Jan 13. Mol Cancer Res. 2017. PMID: 28087741 Free PMC article.

7

Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo.

Yang K, Chen Y, To KK, Wang F, Li D, Chen L, Fu L. Yang K, et al. Exp Mol Med. 2017 Mar 17;49(3):e303. doi: 10.1038/emm.2016.168. Exp Mol Med. 2017. PMID: 28303028 Free PMC article.

8

Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma.

Huang L, Cai M, Zhang X, Wang F, Chen L, Xu M, Yang K, Chen Z, Wang X, Fu L. Huang L, et al. Among authors: yang k. Am J Cancer Res. 2017 Feb 1;7(2):203-217. eCollection 2017. Am J Cancer Res. 2017. PMID: 28337371 Free PMC article.

9

Correction: Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo.

Yang K, Chen Y, To KKW, Wang F, Li D, Chen L, Fu L. Yang K, et al. Exp Mol Med. 2020 Jun;52(6):989-990. doi: 10.1038/s12276-020-0453-6. Exp Mol Med. 2020. PMID: 32555512 Free PMC article.

10

Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia.

Yang K, Wang F, Zhang H, Wang X, Chen L, Su X, Wu X, Han Q, Chen Z, Chen ZS, Fu L. Yang K, et al. Front Oncol. 2021 Jan 8;10:588641. doi: 10.3389/fonc.2020.588641. eCollection 2020. Front Oncol. 2021. PMID: 33585207 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17,492 results

Search Page

Filters